ArticleInternational journal of general medicine2025

Feasibility and Safety of Anlotinib Plus Docetaxel versus Docetaxel Monotherapy in Patients with Previously Immunotherapy-Treated NSCLC: A Retrospective Exploratory Study.

Da-Wei Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.